The GLP-1 stigma in India: how a medical breakthrough became a moral panic.

In March 2025, Eli Lilly launched Mounjaro in India. By October, it had become the country's top-selling drug by value — roughly ₹100 crore in a single month, overtaking GSK's Augmentin, on a fraction of the unit volume (Pharmarack data reported by Reuters). For a medication that much of India's public conversation still describes as a vanity shortcut, that is a strange fact. Strange enough to be worth sitting with.

This is a piece of commentary, not a clinical guide. It argues something specific: that India's cultural backlash against GLP-1 medicines — Ozempic, Wegovy, Mounjaro — has been driven less by clinical evidence than by a coalition with real financial reasons to keep obesity framed as a failure of willpower, and that the people who pay most for that framing are not the loudest voices in the debate but the women quietly judged by it. We will name the conflicts of interest using public, on-the-record material, lead with the epidemiology, and try to be fair to the legitimate safety concerns that genuinely exist.

Start with the numbers, because the numbers are the whole argument

The ICMR-INDIAB-17 study, published in The Lancet Diabetes & Endocrinology in June 2023 (Anjana et al.), is the most authoritative map of India's metabolic health. It estimated that in 2021 India had 101 million people with diabetes, 136 million with prediabetes, 315 million with hypertension, 254 million with generalised obesity, and 351 million with abdominal obesity. Lead author Dr R.M. Anjana has noted that in the Indian population, conversion from prediabetes to diabetes is unusually fast — more than 60% of people with prediabetes convert within five years.

A UNICEF national media roundtable in September 2025 reported that adult obesity in India had risen 91% among women and 146% among men over the measured period. The World Obesity Federation projects obesity-related costs reaching around 2.5% of Indian GDP by 2060. The American Medical Association classified obesity as a disease in 2013; the WHO has long treated it as a chronic, relapsing condition.

This is the floor on which everything else stands. A country with this disease burden cannot honestly treat its most effective new pharmacological tool as a scandal. And yet that is roughly where a large part of the discourse sits.

The Karan Johar episode, and what it revealed

The discourse crystallised around a single celebrity exchange. On Raj Shamani's podcast in May 2025, Karan Johar addressed the persistent speculation about his visible transformation, saying he had "always been battling the bulge," had "tried a thousand different diets and five hundred workouts," and was "tired" of being asked whether he was on Ozempic or Mounjaro. He attributed the change to a previously undiagnosed thyroid condition, a one-meal-a-day regimen, and the elimination of lactose, gluten and sugar.

Whether or not any individual celebrity used a GLP-1 is beside the point — and not our business. What the episode revealed is the structure of the shame: the assumption baked into the question itself, that using medicine would be a thing to hide. When the actor Ram Kapoor addressed similar speculation, he offered a more permissive framing — that even if someone did use medication or surgery, "it is not wrong… people do so to become a better version of themselves." That two public figures could respond to the same insinuation so differently is the entire cultural fault line in miniature.

The most prominent counter-voice

The clearest public pushback has come from the National Award-winning filmmaker Hansal Mehta, who disclosed in May 2025 that he had started Mounjaro after blood tests showed prediabetic glucose levels, losing around 10 kg alongside a high-protein diet, intermittent fasting and strength training. In November 2025 he posted at length on X about the stigma:

"Why has Ozempic or Mounjaro become such a bad word? Why are people ashamed to talk about using modern medicine to manage their health… These medications aren't vanity tools. They are life-saving interventions for metabolic disorders that traditional diets and workouts alone can't always fix. They demand responsibility. Not shame." — Hansal Mehta, on X, 10 November 2025

He put the same point more bluntly in the same thread: "It's not f***ing cocaine." The line went viral precisely because it named the category error at the heart of the backlash — the treatment of a regulated, prescribed, supervised medicine as if it were a recreational drug or a moral shortcut.

Follow the incentives

The most documentable pattern in India's anti-GLP-1 messaging is that several of the loudest voices have direct financial exposure to obesity being understood as a lifestyle problem solvable by coaching, supplements and discipline.

The clearest example is FITTR, the Pune-based online coaching platform, and its founder Jitendra Chouksey. FITTR runs a large network of certified coaches and a six-figure paying client base; the actor Suniel Shetty became a stakeholder in 2019 (when the company was known as SQUATS), and the platform raised Pre-Series A funding from Surge (Sequoia) in 2020. Chouksey filed a Public Interest Litigation in the Delhi High Court challenging GLP-1 approvals. In July 2025 a Division Bench disposed of the PIL with directions to CDSCO/DCGI to examine his representation within three months, with the bench remarking that "drugs with such serious consequences must be regulated" (Medical Dialogues). In a December 2025 interview, Chouksey called GLP-1s "a disaster waiting to unfold," asserted a "real-world dropout rate" of 88%, and was candid about the business stakes:

"We made a conscious choice ten years ago not to build a supplements business. We're taking the same stance today. Whether we stay in the business or go out of business, we're not going to take risks with people." — Jitendra Chouksey, YourStory interview, December 2025

We quote his own words rather than infer his motives. But the structural fact stands on its own: a coaching platform's revenue model rests on the premise that weight loss is achievable through quantified nutrition, behaviour change and accountability — a premise that a medicine producing 20% weight loss without a coach or a subscription does not eliminate, but does materially weaken at the margin. Suniel Shetty's wider portfolio of fitness and nutrition endorsements — across nutraceutical brands, a protein-water startup, and fitness reality television — is built on the same idea: that fitness comes from clean eating, supplements and discipline. That is a public commercial identity, documentable from his own endorsement record, and it is structurally in tension with the proposition that injectable medicine can do most of the work.

None of this makes the safety concerns invalid in themselves — and that distinction matters.

The honest counter-arguments, taken seriously

Two concerns deserve real weight, not dismissal.

Pharmacovigilance and off-label cosmetic use. India does lack robust India-specific safety surveillance for GLP-1s, and the off-label use of a diabetes drug for purely cosmetic weight loss is a legitimate regulatory question. UK adverse-event reporting recorded scores of deaths associated with GLP-1 agonists through 2025 (MHRA Yellow Card data, reported in the BMJ); US litigation over pancreatitis and gastroparesis is real. A drug this powerful, used this widely, this fast, warrants serious oversight. That is exactly what India's regulator has moved toward.

Adherence. This is the strongest evidence-based criticism. The largest real-world analysis to date (Rodriguez et al., JAMA Network Open 2025, 125,474 US adults) found that 46.5% of patients with type 2 diabetes and 64.8% without discontinued within one year; by two years, rates rose to 64.1% and 84.4%. Chouksey's "88%" sits at the very top of that range and is only reachable by benchmarking to two-year non-diabetic discontinuation. Presented as a flat "real-world dropout rate" with no time horizon, it is a rhetorical compression rather than a clean statistic.

But the medical answer to adherence drop-off is not to deny the drug. It is to build the wraparound coaching, side-effect management and tapering protocols that turn a 65% one-year discontinuation into something far lower. Which is, ironically, exactly the kind of structured support a good coaching model is well-placed to provide — if it chose to work alongside the medicine rather than against it.

What the regulator actually did

It is worth being precise here, because "ban" language circulates loosely. Through 2025-26, the CDSCO tightened oversight rather than restricting access. A March 2026 advisory reaffirmed Schedule H prescription-only status, required Risk Management Plans from manufacturers, warned that "awareness campaigns" functioning as surrogate advertising for prescription drugs would be treated as misleading marketing, and classified influencer and celebrity endorsement as indirect advertising under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. The DCGI inspected dozens of online pharmacies, wholesalers and wellness clinics.

What India did not do is reclassify GLP-1s to Schedule H1 — the more restrictive category typically reserved for select antibiotics, anti-TB drugs and psychotropics. The drug consultative process endorsed the advisory rather than escalating the scheduling. In other words: tighter supervision, not prohibition. That is a defensible regulatory posture, and notably it is also roughly what India's own medical bodies have asked for.

The doctors are not the ones panicking

India's professional bodies have endorsed GLP-1 pharmacotherapy — they simply want it used under supervision. The Endocrine Society of India's 2025 obesity guidelines explicitly incorporate semaglutide and tirzepatide as pharmacological options. The RSSDI has long recommended GLP-1 analogues as add-ons for obese patients with type 2 diabetes above defined BMI thresholds. Leading endocrinologists have described semaglutide as a disease-modifying biologic to be used carefully, not banned. The contrast is instructive: the clinical establishment treats these drugs as serious medicine requiring serious oversight, while a chunk of the wellness-and-celebrity establishment treats them as a moral scandal.

The science the stigma ignores

The efficacy data is not ambiguous. In the head-to-head SURMOUNT-5 trial (NEJM 2025), 751 adults with obesity but without diabetes were randomised to tirzepatide or semaglutide for 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide; 81.6% of tirzepatide patients lost at least 10% of body weight, versus 60.5% on semaglutide.

The deeper point is about why diet-and-willpower so often fails. Obesity carries substantial genetic loading — a meta-analysis of 88 twin studies (n≈140,000) estimated heritability around 0.75, and Bouchard's review put the genetic contribution at 40-50% of body-weight variability in the general population, rising to 60-80% among people with severe obesity. And the body actively defends its weight: the famous "Biggest Loser" follow-up (Fothergill et al., Obesity 2016) found that six years after the competition, contestants' resting metabolic rates remained suppressed and most had regained substantial weight — empirical evidence that sustained caloric restriction triggers compensatory metabolic adaptation that persists for years. GLP-1 receptor agonism partially circumvents exactly that adaptation. This is the same intellectual move cardiology made decades ago: statins were once dismissed as the lazy way out of dietary discipline; heart disease itself was once moralised as a "Type A personality" failing before it was understood as arterial biology.

Who actually pays for the stigma

The Indian discourse around women's weight is structurally different from the one around men's, and this is where the moralising frame does its most measurable harm. Matrimonial advertisements continue to state explicit preferences for "slim" brides; Dove's India "Stop the Beauty Test" work found a large majority of Indian women wanted matrimonial sites to ban words like "slim," "tall" and "fair." The joint family extends a continuous surveillance network around a young woman's body in a way it rarely does around a man's; the pre-wedding diet industry — keto camps, "shaadi diets," wheat-free regimens — is well documented.

The cultural geometry is clear. When men lose weight on a GLP-1, the debate is whether it counts. When women do, the debate moves quickly to whether they should have needed to, whether they will now be "too thin," what the in-laws will say. The "log kya kahenge" framework — what will people say — operationalises body judgment as a network of surveillance. And it has a clinical dimension that is easy to miss: chronic anxiety about social judgment elevates cortisol, disrupts sleep and worsens insulin resistance — the very mechanisms a GLP-1 partially corrects. The stigma, in other words, is not just unkind. It is metabolically counterproductive.

The bottom line

None of this is an argument that GLP-1s are risk-free, that they should be sold without prescription, or that everyone visibly thinner is secretly injecting. It is an argument for treating the disease and not the moral character of the patient — the standard already applied to cholesterol, blood pressure and blood sugar. A country with 101 million diabetics and a fast prediabetes-to-diabetes conversion rate cannot afford to spend its public conversation litigating whether a 20%-weight-loss medicine is "cheating."

The people most harmed by the moral panic are not the celebrities denying use or the founders defending their business models. They are the patients — disproportionately women — who delay effective, supervised treatment because they have absorbed the message that needing medicine is a failure. It isn't. As Hansal Mehta put it: responsibility, not shame.